DYNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Dyne Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$15.23+0.98 (+6.88%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
191M of 187M shares
Institutional holders
246
49 new, 28 sold out
Net institutional buying
16M
In Q2 2026
Insider trades, 12 months
7 buys · 122 sales
Net sold $168.34M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Peter Kolchinsky | 9,714,392 | 8.50% | 13G (passive) amendment | Mar 31, 2025 |
| FMR LLC | 8,908,980 | 5.40% | 13G (passive) | Mar 31, 2026 |
| RTW Investments, LP | 5,218,641 | 5.10% | 13G (passive) amendment | Dec 31, 2024 |
| T. Rowe Price Investment Management, Inc. | 30,785,801 | 18.70% | 13G (passive) amendment | Mar 31, 2026 |
| Janus Henderson Group PLC | 13,647,376 | 8.30% | 13G (passive) amendment | Mar 31, 2026 |
| JANUS HENDERSON GROUP Ltd. | 11,997,738 | 7.30% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 11,489,504 | 7.00% | 13G (passive) amendment | Jun 30, 2026 |
| Abigail P. Johnson | 11,207,000 | 6.80% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DYN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 30,912,287 | 16.55% | $686.56K | +126,486 | 0.45% |
| BlackRock, Inc. | 12,404,330 | 6.64% | $275.50M | +704,460 | 0.00% |
| Jupiter Topco LLC | 11,997,738 | 6.42% | $266.63M | New | 0.11% |
| FMR LLC | 11,207,000 | 6.00% | $248.91M | +2,298,020 | 0.01% |
| State Street Corp | 7,458,263 | 3.99% | $165.65M | +804,517 | 0.00% |
| Orbis Allan Gray Ltd | 7,006,542 | 3.75% | $155.62M | +244,311 | 0.53% |
| Atlas Venture Life Science Advisors, LLC | 6,800,099 | 3.64% | $151.03M | −2,330,366 | 17.14% |
| Vanguard Capital Management LLC | 6,310,969 | 3.38% | $140.17M | −94,100 | 0.00% |
| TCG Crossover Management, LLC | 4,615,144 | 2.47% | $102.50M | – | 2.46% |
| Vanguard Portfolio Management LLC | 4,048,428 | 2.17% | $89.92M | −113,613 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 3,936,806 | 2.11% | $87.44K | +1,608,433 | 0.01% |
| Fcpm Iii Services B.V. | 3,848,256 | 2.06% | $85.47M | −796,130 | 11.39% |
| Geode Capital Management, LLC | 3,743,427 | 2.00% | $83.16M | +239,313 | 0.00% |
| Vestal Point Capital, LP | 3,375,000 | 1.81% | $74.96M | −625,000 | 1.75% |
| Orbimed Advisors LLC | 3,235,684 | 1.73% | $71.86M | +317,800 | 1.33% |
| Frazier Life Sciences Management, L.P. | 3,153,082 | 1.69% | $70.03M | – | 1.53% |
| JPMorgan Chase & Co | 3,151,656 | 1.69% | $67.15M | −101,817 | 0.00% |
| Armistice Capital, LLC | 3,087,226 | 1.65% | $68.57M | −87,884 | 0.84% |
| Perceptive Advisors LLC | 2,689,235 | 1.44% | $59.73M | −1,979,604 | 0.90% |
| Logos Global Management LP | 2,550,000 | 1.37% | $56.64M | +1,150,000 | 2.44% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 246 | 191M | 100.0% | 49 / 88 | 76 / 28 | 30M | 14M |
| Q1 2026 | 228 | 188M | 100.0% | 42 / 102 | 59 / 45 | 40M | 21M |
| Q4 2025 | 233 | 181M | 96.8% | 59 / 95 | 59 / 28 | 52M | 30M |
| Q3 2025 | 207 | 159M | 85.2% | 39 / 110 | 39 / 27 | 48M | 18M |
| Q2 2025 | 197 | 129M | 69.1% | 23 / 94 | 54 / 30 | 21M | 14M |
| Q1 2025 | 205 | 122M | 65.4% | 50 / 81 | 44 / 43 | 34M | 23M |
| Q4 2024 | 200 | 112M | 59.8% | 38 / 68 | 63 / 34 | 10M | 10M |
| Q3 2024 | 200 | 113M | 60.3% | 42 / 74 | 54 / 34 | 26M | 18M |
| Q2 2024 | 193 | 112M | 60.0% | 47 / 80 | 45 / 21 | 25M | 11M |
| Q1 2024 | 169 | 97M | 52.1% | 62 / 69 | 27 / 16 | 39M | 15M |
| Q4 2023 | 124 | 73M | 39.2% | 25 / 44 | 39 / 14 | 19M | 5M |
| Q3 2023 | 114 | 60M | 32.1% | 10 / 47 | 32 / 14 | 5M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of DYN | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 7,004,602 | 3.75% | $155.57M | 1.67% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 4,602,629 | 2.46% | $102.22M | 0.97% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,471,727 | 2.39% | $99.32M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 4,152,258 | 2.22% | $92.22M | 0.86% | Jun 30, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 3,809,721 | 2.04% | $84.61M | 1.68% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,550,251 | 1.90% | $78.85M | 0.10% | Jun 30, 2026 |
| T. Rowe Price Capital Appreciation Fund | 3,279,669 | 1.76% | $72.84M | 0.10% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 2,862,005 | 1.53% | $55.32M | 0.06% | May 31, 2026 |
| Vanguard Health Care Fund | 2,808,140 | 1.50% | $70.71M | 0.19% | Jul 31, 2026 |
| Janus Henderson Global Life Sciences Fund | 2,272,649 | 1.22% | $50.48M | 0.87% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,883,544 | 1.01% | $36.41M | 0.69% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 1,690,072 | 0.91% | $37.54M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,656,555 | 0.89% | $41.71M | 0.12% | Jul 31, 2026 |
| Vanguard Small-Cap Index Fund | 1,609,880 | 0.86% | $35.76M | 0.02% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,233,541 | 0.66% | $27.40M | 0.19% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John Cox | CEO & President, Director | 429,507 | 0.23% | Sep 8, 2026 |
| Douglas Kerr | Chief Medical Officer | 162,564 | 0.09% | Sep 8, 2026 |
| Johanna Friedl-Naderer | Chief Commercial Officer | 152,897 | 0.08% | Sep 8, 2026 |
| Erick Lucera | Chief Financial Officer | 119,766 | 0.06% | Aug 17, 2026 |
| Richard William Scalzo | SVP, Head of Finance & Admin. | 122,330 | 0.07% | Mar 13, 2025 |
| Oxana Beskrovnaya | Chief Scientific Officer | 195,840 | 0.10% | Mar 13, 2025 |
| Jason P. Rhodes | Director | 428,946 | 0.23% | Aug 17, 2026 |
| Dirk Kersten | Director | 3,592,184 | 1.92% | Jul 29, 2026 |
| Barry E. Greene | Director | – | – | Jun 23, 2026 |
| David Charles Lubner | Director | 0 | – | Jun 9, 2026 |
| Brian S. Posner | Director | 24,500 | 0.01% | Jun 9, 2026 |
| Edward Hurwitz | Director | 4,614,943 | 2.47% | Jun 9, 2026 |
| Catherine Stehman-Breen | Director | 115,713 | 0.06% | Jun 9, 2026 |
| Carlo Incerti | Director | 0 | – | Jun 9, 2026 |
| Vikram Karnani | Director | – | – | Dec 23, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Douglas Kerr Chief Medical Officer | Sep 8, 2026 | Sale(10b5-1 plan) | −1,290 | $18.88 | $24.36K | 162,564 |
| Johanna Friedl-Naderer Chief Commercial Officer | Sep 8, 2026 | Sale(10b5-1 plan) | −185 | $18.88 | $3.49K | 152,897 |
| John Cox CEO & President, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −5,658 | $18.88 | $106.82K | 357,507 |
| Douglas Kerr Chief Medical Officer | Sep 4, 2026 | Sale(10b5-1 plan) | −3,745 | $24.35 | $91.19K | 163,854 |
| Johanna Friedl-Naderer Chief Commercial Officer | Sep 4, 2026 | Sale(10b5-1 plan) | −900 | $24.35 | $21.92K | 153,082 |
| Jason P. Rhodes Director | Aug 14, 2026 | Sale(10b5-1 plan) | −322,465 | $25.00 | $8.06M | 428,946 |
| Jason P. Rhodes Director | Aug 14, 2026 | Sale(10b5-1 plan) | −478,377 | $25.00 | $11.96M | 567,358 |
| Jason P. Rhodes Director | Aug 14, 2026 | Sale(10b5-1 plan) | −1,359,674 | $25.00 | $33.99M | 2,441,454 |
| Jason P. Rhodes Director | Aug 13, 2026 | Sale(10b5-1 plan) | −63,643 | $26.20 | $1.67M | 751,411 |
| Jason P. Rhodes Director | Aug 13, 2026 | Sale(10b5-1 plan) | −94,415 | $26.20 | $2.47M | 1,045,735 |
| Jason P. Rhodes Director | Aug 13, 2026 | Sale(10b5-1 plan) | −268,354 | $26.20 | $7.03M | 3,801,128 |
| Johanna Friedl-Naderer Chief Commercial Officer | Aug 13, 2026 | Sale(10b5-1 plan) | −226 | $26.28 | $5.94K | 153,982 |
| Douglas Kerr Chief Medical Officer | Aug 13, 2026 | Sale(10b5-1 plan) | −1,556 | $26.28 | $40.89K | 167,599 |
| John Cox CEO & President, Director | Aug 13, 2026 | Sale(10b5-1 plan) | −4,986 | $26.28 | $131.03K | 363,165 |
| Erick Lucera Chief Financial Officer | Aug 13, 2026 | Sale(10b5-1 plan) | −1,797 | $26.28 | $47.23K | 119,766 |
| Dirk Kersten Director | Jul 27, 2026 | Sale(10b5-1 plan) | −256,072 | $25.50 | $6.53M | 3,592,184 |
| Dirk Kersten Director | Jul 27, 2026 | Sale(10b5-1 plan) | −5,388 | $26.04 | $140.30K | 3,586,796 |
| Jason P. Rhodes Director | Jul 7, 2026 | Sale(10b5-1 plan) | −5,000 | $23.61 | $118.05K | 2,962 |
| Jason P. Rhodes Director | Jul 7, 2026 | Sale(10b5-1 plan) | −124,379 | $23.17 | $2.88M | 4,099,069 |
| Jason P. Rhodes Director | Jul 7, 2026 | Sale(10b5-1 plan) | −29,587 | $23.62 | $698.84K | 4,069,482 |
| Jason P. Rhodes Director | Jul 7, 2026 | Sale(10b5-1 plan) | −11,665 | $23.62 | $275.53K | 815,054 |
| Jason P. Rhodes Director | Jul 7, 2026 | Sale(10b5-1 plan) | −49,193 | $23.17 | $1.14M | 826,719 |
| Jason P. Rhodes Director | Jul 7, 2026 | Sale(10b5-1 plan) | −14,844 | $23.62 | $350.62K | 1,140,150 |
| Jason P. Rhodes Director | Jul 7, 2026 | Sale(10b5-1 plan) | −62,543 | $23.17 | $1.45M | 1,154,994 |
| Jason P. Rhodes Director | Jul 6, 2026 | Sale(10b5-1 plan) | −100,019 | $22.79 | $2.28M | 875,912 |
| Jason P. Rhodes Director | Jul 6, 2026 | Sale(10b5-1 plan) | −253,039 | $22.79 | $5.77M | 4,223,448 |
| Jason P. Rhodes Director | Jul 6, 2026 | Sale(10b5-1 plan) | −127,182 | $22.79 | $2.90M | 1,217,537 |
| Jason P. Rhodes Director | Jun 29, 2026 | Sale(10b5-1 plan) | −51,756 | $21.14 | $1.09M | 1,344,719 |
| Jason P. Rhodes Director | Jun 29, 2026 | Sale(10b5-1 plan) | −40,702 | $21.14 | $860.44K | 975,931 |
| Jason P. Rhodes Director | Jun 29, 2026 | Sale(10b5-1 plan) | −102,969 | $21.14 | $2.18M | 4,476,487 |
| Jason P. Rhodes Director | Jun 26, 2026 | Sale(10b5-1 plan) | −64,411 | $21.28 | $1.37M | 1,016,633 |
| Jason P. Rhodes Director | Jun 26, 2026 | Sale(10b5-1 plan) | −81,903 | $21.28 | $1.74M | 1,396,475 |
| Jason P. Rhodes Director | Jun 26, 2026 | Sale(10b5-1 plan) | −162,954 | $21.28 | $3.47M | 4,579,456 |
| Erick Lucera Chief Financial Officer | Jun 25, 2026 | Sale | −2,362 | $20.37 | $48.11K | 121,563 |
| Jason P. Rhodes Director | Jun 25, 2026 | Sale(10b5-1 plan) | −5,019 | $21.10 | $105.90K | 1,081,044 |
| Jason P. Rhodes Director | Jun 25, 2026 | Sale(10b5-1 plan) | −12,699 | $21.10 | $267.95K | 4,742,410 |
| Jason P. Rhodes Director | Jun 25, 2026 | Sale(10b5-1 plan) | −6,382 | $21.10 | $134.66K | 1,478,378 |
| Jason P. Rhodes Director | Jun 24, 2026 | Sale(10b5-1 plan) | −50,530 | $21.02 | $1.06M | 4,755,109 |
| Jason P. Rhodes Director | Jun 24, 2026 | Sale(10b5-1 plan) | −25,397 | $21.02 | $533.84K | 1,484,760 |
| Jason P. Rhodes Director | Jun 24, 2026 | Sale(10b5-1 plan) | −19,973 | $21.02 | $419.83K | 1,086,063 |
| Jason P. Rhodes Director | Jun 23, 2026 | Sale(10b5-1 plan) | −39,131 | $21.13 | $826.84K | 1,510,157 |
| Jason P. Rhodes Director | Jun 23, 2026 | Sale(10b5-1 plan) | −77,855 | $21.13 | $1.65M | 4,805,639 |
| Jason P. Rhodes Director | Jun 23, 2026 | Sale(10b5-1 plan) | −30,774 | $21.13 | $650.25K | 1,106,036 |
| Dirk Kersten Director | Jun 23, 2026 | Sale(10b5-1 plan) | −71,629 | $21.04 | $1.51M | 3,849,913 |
| Dirk Kersten Director | Jun 23, 2026 | Sale(10b5-1 plan) | −1,657 | $21.47 | $35.58K | 3,848,256 |
| Dirk Kersten Director | Jun 22, 2026 | Sale(10b5-1 plan) | −190,676 | $20.57 | $3.92M | 3,921,542 |
| Dirk Kersten Director | Jun 18, 2026 | Sale(10b5-1 plan) | −46,901 | $20.07 | $941.30K | 4,112,218 |
| Dirk Kersten Director | Jun 17, 2026 | Sale(10b5-1 plan) | −37,454 | $20.14 | $754.32K | 4,159,119 |
| Johanna Friedl-Naderer Chief Commercial Officer | Jun 16, 2026 | Sale(10b5-1 plan) | −145 | $18.33 | $2.66K | 154,208 |
| Douglas Kerr Chief Medical Officer | Jun 16, 2026 | Sale(10b5-1 plan) | −887 | $18.33 | $16.26K | 169,155 |
| John Cox CEO & President, Director | Jun 16, 2026 | Sale(10b5-1 plan) | −2,683 | $18.33 | $49.18K | 368,151 |
| Brian S. Posner Director | Jun 8, 2026 | Buy | +2,000 | $16.94 | $33.88K | 24,500 |
| Brian S. Posner Director | Jun 3, 2026 | Buy | +2,500 | $17.48 | $43.70K | 22,500 |
| Brian S. Posner Director | May 26, 2026 | Buy | +2,000 | $18.21 | $36.42K | 20,000 |
| Brian S. Posner Director | May 20, 2026 | Buy | +2,500 | $17.12 | $42.80K | 18,000 |
| John Cox CEO & President, Director | May 13, 2026 | Sale(10b5-1 plan) | −3,311 | $18.36 | $60.79K | 370,834 |
| Johanna Friedl-Naderer Chief Commercial Officer | May 13, 2026 | Sale(10b5-1 plan) | −228 | $18.36 | $4.19K | 154,353 |
| Douglas Kerr Chief Medical Officer | May 13, 2026 | Sale(10b5-1 plan) | −1,564 | $18.36 | $28.72K | 170,042 |
| Erick Lucera Chief Financial Officer | May 13, 2026 | Sale(10b5-1 plan) | −1,448 | $18.36 | $26.59K | 123,925 |
| Jason P. Rhodes Director | May 6, 2026 | Sale(10b5-1 plan) | −17,244 | $18.18 | $313.50K | 1,136,810 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Douglas Kerr Officer | Sep 8, 2026 | 35 | $661 | Sep 8, 2026 | Restricted Stock Units |
| John Cox Officer | Sep 8, 2026 | 5,658 | $106.84K | Sep 8, 2026 | Restricted Stock Units |
| Douglas Kerr Officer | Sep 4, 2026 | 5,000 | $121.75K | Sep 4, 2026 | Restricted Stock Units |
| Atlas Venture Opportunity Fund II, LP Shareholder | Aug 14, 2026 | 478,377 | $12.42M | Aug 14, 2026 | Private Placement |
| Atlas Venture Fund XI, LP Shareholder | Aug 14, 2026 | 1,359,674 | $35.30M | Aug 14, 2026 | Private Placement |
| Atlas Venture Opportunity Fund I, LP Shareholder | Aug 14, 2026 | 322,465 | $8.37M | Aug 14, 2026 | Private Placement |
| Atlas Venture Opportunity Fund I, LP Shareholder | Aug 13, 2026 | 63,643 | $1.67M | Aug 13, 2026 | Private Placement |
| Atlas Venture Fund XI, LP Shareholder | Aug 13, 2026 | 268,354 | $7.02M | Aug 13, 2026 | Private Placement |
| Atlas Venture Opportunity Fund II, LP Shareholder | Aug 13, 2026 | 94,415 | $2.47M | Aug 13, 2026 | Private Placement |
| Douglas Kerr Officer | Aug 13, 2026 | 2,443 | $64.20K | Aug 13, 2026 | Restricted Stock Units |
| Erick Lucera Officer | Aug 13, 2026 | 1,797 | $47.23K | Aug 13, 2026 | Restricted Stock Units |
| John Cox Officer | Aug 13, 2026 | 4,986 | $131.03K | Aug 13, 2026 | Restricted Stock Units |
| B.V. ForDyne Affiliate | Jul 27, 2026 | 261,460 | $6.67M | Jul 27, 2026 | IPO Conversion of Shares |
| Atlas Venture Opportunity Fund II, LP Shareholder | Jul 7, 2026 | 77,387 | $1.77M | Jul 7, 2026 | Private Placement |
| Atlas Venture Fund XI, LP Shareholder | Jul 7, 2026 | 153,966 | $3.52M | Jul 7, 2026 | Private Placement |